New hope for bile duct cancer: targeted chemo combo shows promise in early trial
NCT ID NCT04005339
First seen Jan 29, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This Phase 2 study is testing a combination of three drugs—nanoliposomal irinotecan, fluorouracil, and leucovorin—in 48 adults with advanced biliary tract cancer that has progressed after initial chemotherapy. The main goal is to see if the treatment can stop the cancer from growing for at least 4 months. The study is active but no longer recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10128, United States
-
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Washington University School of Medicine- Siteman Cancer Center
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nanoliposomal irinotecan combined with fluorouracil and leucovorin
What this could lead to
If successful, this could offer a new second-line treatment option for people with advanced biliary tract cancer whose disease has worsened after initial chemotherapy.
What could go wrong
This is a small, early-phase (Phase 2) study with only 48 participants, so results may not apply to everyone. The drug combination may cause side effects and may not improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.